Conditional replicating cytomegalovirus as a vaccine for CMV
View Patent ↗The present invention relates to methods of inducing an immune response to cytomegalovirus (CMV) using a genetically modified CMV that is conditionally replication defective. The methods of the invention can be used to treat and/or prevent primary CMV infection, infection due to reactivation of a latent CMV and a super-infection of a different strain of CMV that had been previously encountered. The present invention also relates to a replication defective CMV which has been recombinantly altered to allow for external control of viral replication. Compositions comprising the replication defective CMV are also encompassed by the present invention.
1. An immunogenic composition comprising an immunologically effective amount of a conditional replication defective cytomegalovirus (CMV) and a pharmaceutically acceptable carrier, wherein the conditional replication defective CMV comprises:
(a) a pentameric gH complex comprising UL128, UL130, UL131, gH and gL; and
(b) a nucleic acid encoding a first fusion protein between IE1/2 and a destabilizing protein and a second fusion protein between UL51 and the destabilizing protein, wherein the destabilizing protein is FK506-binding protein (FKBP) derivative comprising amino acid substitutions F36V and L106P; wherein the wild type IE1/2 and UL51 are no longer present and wherein the CMV is an attenuated strain that has restored gH complex expression due to a repair of a mutation in the UL131 gene.
2. The immunogenic composition of claim 1 , wherein
(a) the first fusion protein is SEQ ID NO:1 or an amino acid sequence that is at least 95% identical to SEQ ID NO:1; and
(b) the second fusion protein is SEQ ID NO:3 or an amino acid sequence that is at least 95% identical to SEQ ID NO:3.
3. The immunogenic composition of claim 2 , wherein
(a) the first fusion protein is encoded by SEQ ID NO:2 or a nucleic acid sequence that is at least 95% identical to SEQ ID NO:2; and
(b) the second fusion protein is encoded by SEQ ID NO:4 or a nucleic acid sequence that is at least 95% identical to SEQ ID NO:4.
4. The immunogenic composition of claim 3 , wherein the first fusion protein is encoded by SEQ ID NO:2 and the second fusion protein is encoded by SEQ ID NO:4.
5. The immunogenic composition of claim 1 further comprising an adjuvant.
6. The immunogenic composition of claim 1 , wherein the CMV is AD169 that has restored gH complex expression due to a repair of a mutation in the UL131 gene.
7. The immunogenic composition of claim 6 , further comprising an adjuvant.
8. An immunogenic composition comprising an immunologically effective amount of a conditional replication defective cytomegalovirus (CMV) and a pharmaceutically acceptable carrier, wherein the conditional replication defective CMV comprises:
(a) a pentameric gH complex comprising UL128, UL130, UL131, gH and gL; and
(b) a nucleic acid encoding a first fusion protein between an essential protein and a destabilizing protein and a second fusion protein between an essential protein and a destabilizing protein, wherein the first fusion protein comprises SEQ ID NO:1 and the second fusion protein comprises SEQ ID NO:3, wherein the wild type IE1/2 and UL51 are no longer present; and
wherein the CMV is an attenuated strain that has restored gH complex expression due to a repair of a mutation in the UL131 gene.
9. The immunogenic composition of claim 8 , further comprising an adjuvant.
10. The immunogenic composition of claim 8 , wherein the CMV is AD169 that has restored gH complex expression due to a repair of a mutation in the UL131 gene.
11. The immunogenic composition of claim 10 , further comprising an adjuvant.
12. The immunogenic composition of claim 8 , wherein the conditional replication defective CMV has a genome as shown in SEQ ID NO: 14.